Geode Capital Management’s CAMP4 Therapeutics CAMP Stock Holding History

Geode Capital Management’s Portfolio CAMP Stock Details CAMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.64M	Buy	900,802 +105,151	+13%	+$431K	﹤0.01%	3002
2026 Q2	$3.48M	Buy	795,651 +412,830	+108%	+$1.78M	﹤0.01%	3057
2026 Q1	$1.69M	Buy	382,821 +46,528	+14%	+$221K	﹤0.01%	3189
2025 Q4	$2.06M	Buy	336,293 +275,922	+457%	+$1.17M	﹤0.01%	3159
2025 Q3	$181K	Sell	60,371 -14,828	-20%	-$27.5K	﹤0.01%	3956
2025 Q2	$109K	Sell	75,199 -84,403	-53%	-$168K	﹤0.01%	4035
2025 Q1	$638K	Buy	159,602 +14,516	+10%	+$70.2K	﹤0.01%	3458
2024 Q4	$757K	Buy	+145,086	New	+$1.19M	﹤0.01%	3464

Other funds holding CAMP

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Landscape Capital Management Englewood, New Jersey $1.34B AUM 18.69% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Geode Capital Management's CAMP Position: Q3 2026 in Review

Geode Capital Management increased its CAMP4 Therapeutics (CAMP) stake by 13% in Q3 2026, buying an estimated $431K and bringing the position to 900,802 shares worth $3.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3002.

Geode Capital Management first reported a position in CAMP in Q4 2024 and has held it in 8 quarters since. 27 funds tracked by Wall St. Rank hold CAMP as of Q3 2026.

Geode Capital Management held 900,802 shares of CAMP4 Therapeutics worth $3.64M as of Q3 2026.
Geode Capital Management bought 105,151 CAMP4 Therapeutics shares in Q3 2026, an estimated $431K.
CAMP4 Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #3002 holding.
Geode Capital Management first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 8 quarters since.
27 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.